Veronika Vejtasova

Dr. Veronika Vejtasova

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EPEva Polakova
Eva Polakova
VVVeronika Vejtasova
Veronika Vejtasova
JVJosef Veselka
Josef Veselka
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is considered a Mendelian disease, with mainly autosomal dominant inheritance. Most pathogenic variants are usually detected in genes for sarcomeric proteins. Nowadays, the genetic basis of HCM is believed to be rather complex. Thousands of mutations in more than 60 genes have been described in association with HCM. Nevertheless, screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the interpretation of the results difficult. Patients lacking a pathogenic variant are now believed to have non-Mendelian HCM and probably have a better prognosis than patients with sarcomeric pathogenic mutations. Identifying the genetic basis of HCM creates remarkable opportunities to understand how the disease develops, and by extension, how to disrupt the disease progression in the future. The aim of this review is to discuss the brief history and recent advances in the genetics of HCM and the application of molecular genetic testing into common clinical practice.

21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EREthan Rowin
Ethan Rowin
RCRaymond H. Chan
Raymond H. Chan
Michael T. ChinMichael T. Chin
Michael T. Chin
VVVeronika Vejtasova
Veronika Vejtasova
MMMartin S. Maron
Martin S. Maron
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.

Verified
Journal Article
Closed access
VVVeronika Vejtasova
Veronika Vejtasova
JBJiri Bonaventura
Jiri Bonaventura
RTRobert Topalo
Robert Topalo
JVJosef Veselka
Josef Veselka

26 February 2026 in The American Journal of Cardiology
Verified
Journal Article
Closed access
VVVeronika Vejtasova
Veronika Vejtasova
MJMichael Jensovsky
Michael Jensovsky
VZVeronika Zoubkova
Veronika Zoubkova
PPPetra Peldova
Petra Peldova
PVPavel Votypka
Pavel Votypka
JBJiri Bonaventura
Jiri Bonaventura

1 September 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
VVVeronika Vejtasova
Veronika Vejtasova
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
RLRobert Lischke
Robert Lischke
JVJosef Veselka
Josef Veselka
Background: We present an uncommon case of a patient with hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis. The case demonstrates the importance of pre-transplant cardiology workup and the need of interdisciplinary approach in diagnosing the cause of dyspnoea. Case summary: The 52-year-old male patient was diagnosed with idiopathic pulmonary fibrosis in 2019 and gradually became oxygen dependent due to progression of dyspnoea. Bilateral lung transplantation was recommended in 2021. During pre-transplant cardiology workup, the patient was diagnosed with hypertrophic cardiomyopathy with left ventricular outflow tract (LVOT) obstruction. Considering the high surgical risk of the patient, alcohol septal ablation was performed with subsequent decrease of LVOT gradient. Bilateral lung transplantation was successfully performed afterwards. The patient’s symptoms improved to NYHA class II at one year follow-up. Discussion: We present a rare case of combined cause of dyspnoea—coexistence of hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis in one patient. Due to high surgical risk, the patient underwent alcohol septal ablation with successful elimination of LVOT gradient and subsequently bilateral lung transplantation.

1 October 2021 in Primary Care Diabetes
Verified
Journal Article
Closed access
JBJan Broz
Jan Broz
BPBarbora Pelechová
Barbora Pelechová
VVVeronika Vejtasova
Veronika Vejtasova
JMJana Malinovská
Jana Malinovská